Phase 4 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with pulmonary arterial hypertension (a type of high blood pressure affecting the lungs), confirmed through accepted medical and test-based criteria
- People who have been on a stable combination of two specific types of medication — an endothelin receptor antagonist and sildenafil — before the trial begins
- People whose condition is rated as intermediate-low, intermediate-high, or high risk according to a specific medical scoring system called COMPERA 2.0 (confirm with trial site)
- People whose doctors have determined that their current treatment needs to be stepped up or intensified
- People who are able to attend follow-up appointments between 3 and 6 months after joining the trial
- People who are able to give written consent to participate
Who may not be able to join:
- People who are already taking part in another clinical trial that requires changes to their treatment
- People who have a known medical reason why they cannot take a group of medications called prostacyclin pathway agents, including iloprost or selexipag
- People who have a known medical reason why their sildenafil dose cannot be increased
- People who are pregnant or breastfeeding
- Women who could become pregnant and are not using effective contraception
- People with any other health condition that, in the treating doctor's judgement, could interfere with taking part in the trial or affect the results
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Caio Fernandes, Instituto do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo
Phone: +551126615034
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Improvement in Risk Stratification According to the COMPERA 2.0 Four-Stratum Model
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.